This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Friday, May 23, 2014
Tipping Point: The Unprecedented Hepatitis C Situation
Hepatitis C: A Brief Medical Primer
Rena Fox, Professor of Medicine, UCSF @UCSF
Tipping Point: The Unprecedented Hepatitis C Situation
Moderated By: James Hamblin, Senior Editor, The Atlantic
Richard Elion, Clinical Research Director, Whitman-Walker Health
Rena Fox, Professor of Medicine, UCSF
Donald Jensen, Director of the Center for Liver Diseases, University of Chicago
Steven Pearson, President, Institute for Clinical and Economic Review; Visiting Scientist, Department of Bioethics, National Institutes of Health
From AtlanticLIVE
Medicine, the Market, and You
We asked two industry experts a simple question: what are the market-based solutions to the high price of pharmaceuticals?
Source
No comments:
Post a Comment